Switch theme
Sign up to access all valuation multiples
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
2004
n/a
LTM Revenue n/a
LTM EBITDA n/a
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Changchun BCHT has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Changchun BCHT achieved revenue of $251M and an EBITDA of $90.4M.
Changchun BCHT expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Changchun BCHT valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $251M | n/a | XXX | XXX | XXX |
| Gross Profit | $146M | $129M | XXX | XXX | XXX |
| Gross Margin | 58% | NaN% | XXX | XXX | XXX |
| EBITDA | $90.4M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 36% | NaN% | XXX | XXX | XXX |
| Net Profit | $33.6M | $25.0M | XXX | XXX | XXX |
| Net Margin | 13% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Changchun BCHT's stock price is CNY 23 (or $3).
Changchun BCHT has current market cap of CNY 9.4B (or $1.3B), and EV of CNY 9.2B (or $1.3B).
See Changchun BCHT trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Changchun BCHT has market cap of $1.3B and EV of $1.3B.
Changchun BCHT's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Changchun BCHT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Changchun BCHT and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChangchun BCHT's NTM/LTM revenue growth is n/a
Changchun BCHT's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Changchun BCHT's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Changchun BCHT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Changchun BCHT and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 56% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Changchun BCHT acquired XXX companies to date.
Last acquisition by Changchun BCHT was XXXXXXXX, XXXXX XXXXX XXXXXX . Changchun BCHT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Changchun BCHT founded? | Changchun BCHT was founded in 2004. |
| Where is Changchun BCHT headquartered? | Changchun BCHT is headquartered in China. |
| Is Changchun BCHT publicy listed? | Yes, Changchun BCHT is a public company listed on SHG. |
| What is the stock symbol of Changchun BCHT? | Changchun BCHT trades under 688276 ticker. |
| When did Changchun BCHT go public? | Changchun BCHT went public in 2021. |
| Who are competitors of Changchun BCHT? | Similar companies to Changchun BCHT include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Changchun BCHT? | Changchun BCHT's current market cap is $1.3B |
| Is Changchun BCHT profitable? | Yes, Changchun BCHT is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
